PF-AtlasClinical Trials › NCT01772758

Cystic Fibrosis and Endothelial Function: At Rest and During Exercise

BH4 5mg · Phase 2

Registry ID
NCT01772758
Phase
Phase 2
Status
Completed
Drug / intervention
BH4 5mg
Sponsor
Augusta University
Start
2011-08
Enrollment
64
Locations
1

About this trial

Perhaps one of the most disturbing aspects of Cystic Fibrosis (CF) is the associated premature death. Oxidative stress has been observed in patients with CF and exercise intolerance has been shown to predict mortality in patients with CF, regardless of how healthy their lungs are. A critical barrier to improving the quality of life and longevity in patients with CF is our lack of knowledge regarding the different reasons why patients with CF cannot exercise to the level of their peers. We have collected preliminary data to support our central hypothesis that oxidative stress contributes to the impairment in blood vessel function at rest and during exercise which ultimately oxygen transport and delivery resulting in exercise intolerance. Exercise is therapeutic medicine for patients with CF and this investigation represents a major breakthrough in the approach to begin understanding the physiological mechanisms which contribute to exercise intolerance in these patients.

View NCT01772758 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT01772758 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.